Jul 16, 2018 7:00am EDT Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease
May 31, 2018 4:30pm EDT Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology
May 24, 2018 7:00am EDT Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL
May 23, 2018 4:05pm EDT Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology
May 14, 2018 7:00am EDT Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update
May 7, 2018 7:00am EDT Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention
May 1, 2018 7:00am EDT Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease
Apr 4, 2018 7:00am EDT Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York
Apr 3, 2018 7:00am EDT Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
